NCT07204847Completed
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI
Prognostic Impact of Guideline-recommended Timing for Invasive Strategy in NSTEMI: a Prospective Real-world Study
Source: ClinicalTrials.gov · Last updated 2 Oct 2025
Brief summary (registry, in English)
The objective of this multicentric observational study is to evaluate the prognostic influence of adherence or non-adherence to the recommended coronary angiography timeframe (within 24 hours) and the six-month prognosis of the patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 407 (actual)
- First submitted
- 15 Sept 2025
- Start date
- 1 Nov 2023
- Primary completion date
- 1 May 2025
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Coronary artery disease
- NCT number
- NCT07204847
What you commit to
- Study type: Observational
- Participants enrolled: 407
- From 1 Nov 2023 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- STEMI (ST-segment elevation myocardial infarction) or equivalent (defined as chest pain with ECG changes and troponin elevation \> 5 times the normal with an occluded artery (TIMI 0, 1, or 2) during initial coronary angiography)
- Very high-risk NSTEMI (hemodynamic instability, cardiogenic shock, recurrent/refractory chest pain despite optimal medical treatment, life-threatening arrhythmia, mechanical complication, heart failure clearly related to NSTEMI, ST depression \> 1mm/6 leads with ST elevation in aVR and/or V1) for which urgent coronary angiography is mandatory
- Unstable angina (acute coronary syndrome without troponin elevation)
- Recovered cardiac arrest
- Other diagnoses considered after coronary angiography (e.g., myocarditis, Takotsubo syndrome)
Age
- Age \< 18 years
Other
- Troponin elevation without chest pain or symptoms suggestive of NSTEMI
- Contraindication to coronary revascularization or coronary angiography
Who the study is looking for
- Presence of chest pain with or without ECG changes
- Elevation of troponin level \> 90th percentile or a significant increase between two dosages
- Significant or non-significant coronary lesion confirming the diagnosis of coronary artery disease on coronary angiography (coronary angiography mandatory before inclusion to confirm NSTEMI)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Montpellier Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.